FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386371390> ?p ?o ?g. }

• W4386371390 endingPage "4374" @default.
• W4386371390 startingPage "4374" @default.
• W4386371390 abstract "Breast cancer (BC) is the most common malignancy among women worldwide. Around 15-25% of BC overexpress the human epidermal growth factor receptor 2 (HER2), which is associated with a worse prognosis and shortened disease-free survival. Therefore, anti-HER2 therapies have been developed, such as monoclonal antibodies (trastuzumab, Tz), antibody-drug conjugates (ado-trastuzumab emtansine, T-DM1), and pharmacological inhibitors of tyrosine kinase activity (lapatinib, Lp). Although Tz, the standard treatment, has significantly improved the prognosis of patients, resistance still affects a significant population of women and is currently a major challenge in clinical oncology. Therefore, this study aims to identify potential biomarkers to predict disease progression (prognostic markers) and the efficacy of Tz treatment (predictive markers) in patients with HER2+ BC. We hypothesize that proteins involved in cell motility are implicated in Tz-resistance. We aim to identify alterations in Tz-resistant cells to guide more efficient oncologic decisions. By bioinformatics, we selected candidate proteins and determined how their expression, localization, and the process they modulate were affected by anti-HER2 treatments. Next, using HER2+ BC patients' data, we assessed these proteins as prognostic and predictive biomarkers. Finally, using Tz-resistant cells, we evaluated their roles in Tz response. We identified deregulated genes associated with cell motility in Tz/T-DM1-resistant vs. -sensitive cells. We showed that Tz, T-DM1, and Lp decrease cell viability, and their effect is enhanced in combinations. We determined synergism between Tz/T-DM1 and Lp, making possible a dose reduction of each drug to achieve the same therapeutic effect. We found that combinations (Tz/T-DM1 + Lp) efficiently inhibit cell adhesion and migration. Furthermore, we demonstrated the induction of FAK nuclear and cortactin peri-nuclear localization after T-DM1, Lp, and Tz/T-DM1 + Lp treatments. In parallel, we observed that combined treatments downregulate proteins essential for metastatic dissemination, such as SRC, FAK, and paxillin. We found that low vinculin (VCL) and cortactin (CTTN) mRNA expression predicts favorable survival rates and has diagnostic value to discriminate between Tz-sensible and Tz-resistant HER2+ BC patients. Finally, we confirmed that vinculin and cortactin are overexpressed in Tz-resistance cells, SKBR3-RTz. Moreover, we found that Tz plus FAK/paxillin/cortactin-silencing reduced cell adhesion/migration capacity in Tz-sensitive and -resistant cells. In conclusion, we demonstrate that combined therapies are encouraging since low doses of Tz/T-DM1 + Lp inhibit metastatic processes by downregulating critical protein expression and affecting its subcellular localization. We propose that vinculin and cortactin might contribute to Tz-sensibility/resistance in BC cells. Finally, we identify potential prognostic and predictive biomarkers that are promising for personalized BC management that would allow efficient patient selection in order to mitigate resistance and maximize the safety and efficacy of anti-HER2 therapies." @default.
• W4386371390 created "2023-09-02" @default.
• W4386371390 creator A5015010558 @default.
• W4386371390 creator A5089311584 @default.
• W4386371390 creator A5090082371 @default.
• W4386371390 date "2023-09-01" @default.
• W4386371390 modified "2023-10-06" @default.
• W4386371390 title "Potential Biomarkers Associated with Prognosis and Trastuzumab Response in HER2+ Breast Cancer" @default.
• W4386371390 cites W1541670869 @default.
• W4386371390 cites W1890447094 @default.
• W4386371390 cites W1968590850 @default.
• W4386371390 cites W1983178737 @default.
• W4386371390 cites W1984007340 @default.
• W4386371390 cites W1997381761 @default.
• W4386371390 cites W1999247203 @default.
• W4386371390 cites W1999353750 @default.
• W4386371390 cites W2010251891 @default.
• W4386371390 cites W2012915718 @default.
• W4386371390 cites W2030870003 @default.
• W4386371390 cites W2032894034 @default.
• W4386371390 cites W2036435832 @default.
• W4386371390 cites W2041544427 @default.
• W4386371390 cites W2064086110 @default.
• W4386371390 cites W2069707480 @default.
• W4386371390 cites W2077804275 @default.
• W4386371390 cites W2083486298 @default.
• W4386371390 cites W2089288294 @default.
• W4386371390 cites W2094646101 @default.
• W4386371390 cites W2096439168 @default.
• W4386371390 cites W2098791934 @default.
• W4386371390 cites W2100239923 @default.
• W4386371390 cites W2103521510 @default.
• W4386371390 cites W2103562758 @default.
• W4386371390 cites W2110444464 @default.
• W4386371390 cites W2118385988 @default.
• W4386371390 cites W2125550817 @default.
• W4386371390 cites W2129788875 @default.
• W4386371390 cites W2131487381 @default.
• W4386371390 cites W2141393790 @default.
• W4386371390 cites W2146512944 @default.
• W4386371390 cites W2155560234 @default.
• W4386371390 cites W2159967578 @default.
• W4386371390 cites W2162232981 @default.
• W4386371390 cites W2162371443 @default.
• W4386371390 cites W2162488896 @default.
• W4386371390 cites W2169344919 @default.
• W4386371390 cites W2172415870 @default.
• W4386371390 cites W2318605753 @default.
• W4386371390 cites W2337221009 @default.
• W4386371390 cites W2344341820 @default.
• W4386371390 cites W2391616294 @default.
• W4386371390 cites W2411861865 @default.
• W4386371390 cites W2586407709 @default.
• W4386371390 cites W2755672107 @default.
• W4386371390 cites W2765729492 @default.
• W4386371390 cites W2806273362 @default.
• W4386371390 cites W2900569176 @default.
• W4386371390 cites W2902218997 @default.
• W4386371390 cites W2918012424 @default.
• W4386371390 cites W2924993030 @default.
• W4386371390 cites W2941467331 @default.
• W4386371390 cites W2944602336 @default.
• W4386371390 cites W2949922878 @default.
• W4386371390 cites W2977567559 @default.
• W4386371390 cites W2979291688 @default.
• W4386371390 cites W3001369781 @default.
• W4386371390 cites W3021909056 @default.
• W4386371390 cites W3047974101 @default.
• W4386371390 cites W3110917833 @default.
• W4386371390 cites W3125116437 @default.
• W4386371390 cites W3126503636 @default.
• W4386371390 cites W3162350134 @default.
• W4386371390 cites W3163557740 @default.
• W4386371390 cites W3172143512 @default.
• W4386371390 cites W3202334206 @default.
• W4386371390 cites W3202618708 @default.
• W4386371390 cites W4210984918 @default.
• W4386371390 cites W4221083316 @default.
• W4386371390 cites W4297225374 @default.
• W4386371390 cites W4306836209 @default.
• W4386371390 cites W4312194612 @default.
• W4386371390 cites W4320494598 @default.
• W4386371390 doi "https://doi.org/10.3390/cancers15174374" @default.
• W4386371390 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37686651" @default.
• W4386371390 hasPublicationYear "2023" @default.
• W4386371390 type Work @default.
• W4386371390 citedByCount "0" @default.
• W4386371390 crossrefType "journal-article" @default.
• W4386371390 hasAuthorship W4386371390A5015010558 @default.
• W4386371390 hasAuthorship W4386371390A5089311584 @default.
• W4386371390 hasAuthorship W4386371390A5090082371 @default.
• W4386371390 hasBestOaLocation W43863713901 @default.
• W4386371390 hasConcept C121608353 @default.
• W4386371390 hasConcept C126322002 @default.
• W4386371390 hasConcept C143998085 @default.
• W4386371390 hasConcept C2777329042 @default.
• W4386371390 hasConcept C2778087150 @default.
• W4386371390 hasConcept C2779438470 @default.

• next